Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Zeromskiego 113, 90-549, Lodz, Poland.
Drugs. 2014 Jun;74(9):971-80. doi: 10.1007/s40265-014-0233-5.
Trimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in patients with stable ischemic heart disease, has been the source of much controversy in recent years; some have gone so far as to treat the medication as a 'placebo drug' whose new side effects, such as Parkinsonian symptoms, outweigh its benefits. This article is an attempt to present the recent key studies, including meta-analyses, on the use of trimetazidine in chronic heart failure, also in patients with diabetes mellitus and arrhythmia, as well as in peripheral artery disease. This paper also includes the most recent European Society of Cardiology guidelines, including those of 2013, on the use of trimetazidine in cardiovascular disease.
曲美他嗪是一种细胞保护药物，其在心脑血管方面的有效性，尤其是在稳定性缺血性心脏病患者中，近年来一直存在很大争议；有人甚至将该药物视为“安慰剂药物”，其新的副作用，如帕金森症状，超过了其益处。本文试图介绍曲美他嗪在慢性心力衰竭中的最新关键研究，包括荟萃分析，以及在糖尿病和心律失常患者以及外周动脉疾病中的应用。本文还包括欧洲心脏病学会最新指南，包括 2013 年的指南，介绍了曲美他嗪在心血管疾病中的应用。
